JY
CGON icon

Jeff Yass’s CG Oncology CGON Stock Holding History

Jeff Yass’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Sell
15,653
-10,150
-39% -$663K ﹤0.01% 7927
2026
Q1 		$1.75M Buy
+25,803
New +$1.46M ﹤0.01% 6488
2025
Q3 		– Sell
-93,793
Closed -$2.73M – 12530
2025
Q2 		$2.44M Buy
93,793
+11,808
+14% +$285K ﹤0.01% 5376
2025
Q1 		$2.01M Buy
81,985
+44,316
+118% +$1.25M ﹤0.01% 5536
2024
Q4 		$1.08M Buy
37,669
+24,676
+190% +$844K ﹤0.01% 6755
2024
Q3 		$490K Buy
+12,993
New +$455K ﹤0.01% 8508
2024
Q2 		– Sell
-11,149
Closed -$386K – 12125
2024
Q1 		$489K Buy
+11,149
New +$455K ﹤0.01% 8569

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's CGON Position: Q2 2026 in Review

Jeff Yass reduced its CG Oncology (CGON) stake by 39% in Q2 2026, selling an estimated $663K and leaving 15,653 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #7927.

Jeff Yass first reported a position in CGON in Q1 2024 and has held it in 7 quarters since. The position peaked at $2.44M in Q2 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Jeff Yass held 15,653 shares of CG Oncology worth $1.11M as of Q2 2026.
  • Jeff Yass sold 10,150 CG Oncology shares in Q2 2026, an estimated $663K.
  • CG Oncology made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7927 holding.
  • Jeff Yass first reported a position in CG Oncology in Q1 2024 and has held it in 7 quarters since.
  • Jeff Yass's CG Oncology position peaked at $2.44M in Q2 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.